Novavax (NVAX) Expected to Announce Earnings on Thursday

Novavax (NASDAQ:NVAX) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Novavax to post earnings of ($0.66) per share and revenue of $90.2580 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Novavax Price Performance

NASDAQ:NVAX opened at $9.36 on Tuesday. Novavax has a 12-month low of $5.01 and a 12-month high of $10.64. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of 5.23 and a beta of 2.58. The stock’s 50 day moving average price is $8.06 and its two-hundred day moving average price is $7.98. The company has a quick ratio of 2.24, a current ratio of 2.27 and a debt-to-equity ratio of 5.93.

Institutional Investors Weigh In On Novavax

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quarry LP bought a new stake in shares of Novavax in the third quarter valued at approximately $33,000. Danske Bank A S acquired a new position in Novavax in the 3rd quarter valued at $64,000. State of Wyoming acquired a new position in Novavax in the 2nd quarter valued at $52,000. Scientech Research LLC bought a new stake in shares of Novavax during the 3rd quarter valued at $96,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Novavax during the 4th quarter valued at $75,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVAX has been the topic of a number of research analyst reports. TD Cowen dropped their price target on Novavax from $8.00 to $7.00 and set a “hold” rating on the stock in a research note on Tuesday, November 4th. Wall Street Zen downgraded shares of Novavax from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Weiss Ratings restated a “sell (d+)” rating on shares of Novavax in a research note on Monday, December 29th. JPMorgan Chase & Co. reduced their target price on shares of Novavax from $7.00 to $6.00 and set an “underweight” rating for the company in a report on Tuesday, November 18th. Finally, B. Riley Financial reiterated a “buy” rating and issued a $16.00 price target (down previously from $18.00) on shares of Novavax in a research note on Monday, November 10th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, Novavax currently has a consensus rating of “Hold” and a consensus price target of $11.25.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.